FDA Approves A New Class of Lipid-Lowering Drugs – PCSK9 Inhibitors

By  |  0 Comments

Heart Health News!! One out of three American adults is estimated to have high LDL cholesterol, according to the Centers for Disease Control and Prevention. Elevated LDL cholesterol is recognized as a major risk factor for cardiovascular disease, which remains the leading cause of death worldwide.   In the United States, 1 in 4 women dies from heart disease.

The FDA granted marketing approval on Thursday to evolocumab (Repatha), the second in a new class of lipid-lowering drugs — PCSK9 inhibitors. These drugs appear to sharply reduce levels of bad (LDL) cholesterol. Clinical trials of PCSK9 inhibitor drugs developed by Amgen, Sanofi and Regeneron demonstrate LDL levels are reduced by 60%. By comparison, statins — the current class of drugs that are the mainstay of treatment for high LDL — generally reduce LDL levels by 30-50%.

At this point, these new drugs appear to be quite costly.  However, it is always good to know the latest options available so that you and your healthcare professional can develop the best plan of action for your individual heart health needs.

After struggling with her own severe menopause symptoms and doing years of research, Ellen resolved to share what she learned from experts and her own trial and error. Her goal was to replace the confusion, embarrassment, and symptoms millions of women go through–before, during, and after menopause–with the medically sound solutions she discovered. Her passion to become a “sister” and confidant to all women fueled Ellen’s first book, Shmirshky: the pursuit of hormone happiness. As a result of the overwhelming response from her burgeoning audiences and followers’ requests for empowering information they could trust, Ellen’s weekly blog, Menopause MondaysTM, was born.

MENOPAUSE MONDAYS™
Sign up here to receive Ellen Dolgen's Menopause Mondays™.
Suffering in silence is OUT! Reaching out is IN!
We respect your privacy. We NEVER spam.